A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs OMO 103 (Primary)
- Indications Osteosarcoma
- Focus Proof of concept; Therapeutic Use
- 24 Oct 2024 New trial record